Today, Narwhal Capital Management Buys 1,780 Shares of Gilead Sciences Inc. (GILD)

Today, Narwhal Capital Management Buys 1,780 Shares of Gilead Sciences Inc. (GILD)

Narwhal Capital Management raised its position in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 6.6% during the third quarter, according to its most recent filing with the SEC. The fund owned 28,600 shares of the biopharmaceutical company’s stock after buying an additional 1,780 shares during the period. Narwhal Capital Management’s holdings in Gilead Sciences were worth $2,263,000 at the end of the most recent reporting period.

A number of other institutional investors have also made changes to their positions in GILD. CWM LLC boosted its position in shares of Gilead Sciences by 0.6% in the second quarter. CWM LLC now owns 2,957 shares of the biopharmaceutical company’s stock worth $247,000 after buying an additional 17 shares during the last quarter. Tarbox Group Inc. boosted its position in shares of Gilead Sciences by 0.4% in the third quarter. Tarbox Group Inc. now owns 6,522 shares of the biopharmaceutical company’s stock worth $516,000 after buying an additional 27 shares during the last quarter. Cadence Bank NA boosted its position in shares of Gilead Sciences by 0.8% in the second quarter. Cadence Bank NA now owns 3,727 shares of the biopharmaceutical company’s stock worth $311,000 after buying an additional 28 shares during the last quarter. Marble Harbor Investment Counsel LLC boosted its position in shares of Gilead Sciences by 0.9% in the second quarter. Marble Harbor Investment Counsel LLC now owns 3,330 shares of the biopharmaceutical company’s stock worth $278,000 after buying an additional 30 shares during the last quarter. Finally, Birch Hill Investment Advisors LLC boosted its position in shares of Gilead Sciences by 0.9% in the second quarter. Birch Hill Investment Advisors LLC now owns 3,336 shares of the biopharmaceutical company’s stock worth $278,000 after buying an additional 30 shares during the last quarter. 76.65% of the stock is currently owned by hedge funds and other institutional investors.

Gilead Sciences Inc. (NASDAQ:GILD) traded up 0.19% during mid-day trading on Friday, reaching $75.44. 3,068,606 shares of the company’s stock were exchanged. Gilead Sciences Inc. has a 52-week low of $71.39 and a 52-week high of $108.31. The stock has a market cap of $99.39 billion, a price-to-earnings ratio of 6.98 and a beta of 1.25. The company has a 50-day moving average of $74.56 and a 200-day moving average of $80.20.

Gilead Sciences (NASDAQ:GILD) last announced its earnings results on Tuesday, November 1st. The biopharmaceutical company reported $2.75 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $2.87 by $0.12. The firm earned $7.40 billion during the quarter, compared to analysts’ expectations of $7.47 billion. Gilead Sciences had a net margin of 47.74% and a return on equity of 100.57%. The business’s revenue for the quarter was down 9.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.22 EPS. Equities research analysts anticipate that Gilead Sciences Inc. will post $11.47 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 29th. Stockholders of record on Thursday, December 15th will be issued a $0.47 dividend. The ex-dividend date of this dividend is Tuesday, December 13th. This represents a $1.88 annualized dividend and a dividend yield of 2.49%. Gilead Sciences’s dividend payout ratio is currently 17.44%.

Several equities research analysts have weighed in on the stock. Leerink Swann reiterated a “market perform” rating and issued a $89.00 target price on shares of Gilead Sciences in a report on Tuesday, November 15th. Stifel Nicolaus assumed coverage on shares of Gilead Sciences in a report on Monday, November 14th. They issued a “buy” rating and a $100.00 target price on the stock. They noted that the move was a valuation call. Jefferies Group reiterated a “buy” rating on shares of Gilead Sciences in a report on Tuesday, November 8th. Mizuho assumed coverage on shares of Gilead Sciences in a report on Monday, November 7th. They issued a “buy” rating and a $88.00 target price on the stock. Finally, Zacks Investment Research upgraded shares of Gilead Sciences from a “strong sell” rating to a “hold” rating in a report on Monday, November 7th. Ten investment analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and two have given a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $97.90.

In related news, insider John F. Milligan sold 70,000 shares of the firm’s stock in a transaction dated Tuesday, September 6th. The shares were sold at an average price of $77.74, for a total transaction of $5,441,800.00. Following the completion of the sale, the insider now owns 1,128,963 shares in the company, valued at $87,765,583.62. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider John C. Martin sold 100,000 shares of the firm’s stock in a transaction dated Thursday, September 1st. The stock was sold at an average price of $77.48, for a total transaction of $7,748,000.00. Following the sale, the insider now owns 3,287,810 shares of the company’s stock, valued at approximately $254,739,518.80. The disclosure for this sale can be found here. 1.40% of the stock is currently owned by insiders.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

Related posts

Leave a Comment